Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Centrillion Technology Holdings Corporation is currently managing 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 4 distinct examiners and 4 distinct art units, showing a high degree of administrative dispersion for the portfolio's active cases. This distribution indicates that each of the company's 4 pending office actions is being reviewed by a different individual in a separate section of the patent office, which can lead to diverse prosecution results and varying response requirements across the portfolio.
The busiest examiner, PRIEST, AARON A, is responsible for 1 busiest examiner pending office action. With a total of 4 pending office actions, the workload is spread thin across the office, as each of the 4 distinct examiners is only handling a single pending matter for the company. This lack of concentration means that no single examiner or art unit has a dominant influence over the portfolio's current trajectory. Practitioners should be prepared to navigate 4 different examination styles simultaneously, as the data shows no overlap between the 4 distinct examiners or the 4 distinct art units assigned to these matters. The fact that the busiest examiner pending count is 1 while the total actions count is 4 underscores the decentralized nature of the company's current patent prosecution efforts.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOWMAN, ANDREW J | 1 | 65.8% | +13.5% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.7% |
| BUNKER, AMY M | 1 | 29.1% | +45.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 15563015 | METHODS FOR PERFORMING SPATIAL PROFILING OF BIOLOGICAL MOLECULES | BUNKER, AMY M | 49d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 15563015 | METHODS FOR PERFORMING SPATIAL PROFILING OF BIOLOGICAL MOLECULES | BUNKER, AMY M | 49d overdue |
| 17817832 | SYSTEM FOR AUTOMATED SYNTHESIS OF BIOCHIPS | BOWMAN, ANDREW J | 34d |
| 17815725 | REVERSIBLE TERMINATORS FOR DNA SEQUENCING AND METHODS OF USING THE SAME | VANHORN, ABIGAIL LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1717 | 1 |
| 1636 | 1 |
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17817832 | SYSTEM FOR AUTOMATED SYNTHESIS OF BIOCHIPS | BOWMAN, ANDREW J | 1717 | §103 | Final Rejection | 34d | Pending | Aug 05, 2022 |
| 17815725 | REVERSIBLE TERMINATORS FOR DNA SEQUENCING AND METHODS OF USING THE SAME | VANHORN, ABIGAIL LOUISE | 1636 | §103 | Non-Final OA | — | Pending | Jul 28, 2022 |
| 15563015 | METHODS FOR PERFORMING SPATIAL PROFILING OF BIOLOGICAL MOLECULES | BUNKER, AMY M | 1684 | §103§112 | Non-Final OA | 49d overdue | Pending | Sep 29, 2017 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCentrillion Technology Holdings Corporation has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Andrew J Bowman has the most, with 1 of Centrillion Technology Holdings Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
